BWXT Medical and Bayer AG Enter into Agreement for the Development and Production of Actinium-225
(OTTAWA, Ontario – September 16, 2021) – BWX Technologies, Inc. (NYSE: BWXT) announced today that its BWXT Medical Ltd. subsidiary (BWXT Medical) has entered into an agreement with Bayer AG (Bayer) to develop Actinium-225 (Ac-225) supply and further partnering opportunities on finished products as both companies broaden their respective commercialization strategies for targeted radionuclide therapies (TRTs) and other innovative products.
BWXT Medical Enters into a New Long-Term Agreement with Boston Scientific
(Ottawa, Ontario – May 10, 2021) – BWXT Medical Ltd. (BWXT Medical) announced today that it has entered into a new long-term, mutually exclusive agreement to manufacture TheraSphere™ Y-90 Glass Microspheres for Boston Scientific, a leading global medical device company.
BWXT Names Nuclear Medicine Business as BWXT Medical
(LYNCHBURG, Va. – Feb. 1, 2021) – BWX Technologies, Inc. (NYSE: BWXT) today announced that its subsidiary BWXT ITG Canada, Inc., a nuclear medicine company, has been renamed BWXT Medical Ltd. (BWXT Medical), in order to better align with the company’s products, customer base and strategy.